SG11201402763SA - Methods for treating hyperbilirubinemia with stannsoporfin - Google Patents

Methods for treating hyperbilirubinemia with stannsoporfin

Info

Publication number
SG11201402763SA
SG11201402763SA SG11201402763SA SG11201402763SA SG11201402763SA SG 11201402763S A SG11201402763S A SG 11201402763SA SG 11201402763S A SG11201402763S A SG 11201402763SA SG 11201402763S A SG11201402763S A SG 11201402763SA SG 11201402763S A SG11201402763S A SG 11201402763SA
Authority
SG
Singapore
Prior art keywords
stannsoporfin
methods
treating hyperbilirubinemia
hyperbilirubinemia
treating
Prior art date
Application number
SG11201402763SA
Other languages
English (en)
Inventor
Simon J Tulloch
Warren W Wasiewski
Original Assignee
Infacare Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Infacare Pharmaceutical Corp filed Critical Infacare Pharmaceutical Corp
Publication of SG11201402763SA publication Critical patent/SG11201402763SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4836—Diagnosis combined with treatment in closed-loop systems or methods
    • A61B5/4839—Diagnosis combined with treatment in closed-loop systems or methods combined with drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/062—Photodynamic therapy, i.e. excitation of an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/0621—Hyperbilirubinemia, jaundice treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Radiology & Medical Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201402763SA 2011-12-01 2012-11-30 Methods for treating hyperbilirubinemia with stannsoporfin SG11201402763SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161565842P 2011-12-01 2011-12-01
PCT/US2012/067484 WO2013082559A1 (en) 2011-12-01 2012-11-30 Methods for treating hyperbilirubinemia with stannsoporfin

Publications (1)

Publication Number Publication Date
SG11201402763SA true SG11201402763SA (en) 2014-06-27

Family

ID=48536150

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201402763SA SG11201402763SA (en) 2011-12-01 2012-11-30 Methods for treating hyperbilirubinemia with stannsoporfin

Country Status (10)

Country Link
US (2) US20130158362A1 (ja)
EP (2) EP3517115A3 (ja)
JP (3) JP2015500243A (ja)
KR (1) KR20140107355A (ja)
CN (2) CN104080457A (ja)
AU (3) AU2012345646A1 (ja)
CA (1) CA2857153A1 (ja)
IL (2) IL232791B (ja)
SG (1) SG11201402763SA (ja)
WO (1) WO2013082559A1 (ja)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2079472T3 (da) 2006-10-04 2011-10-31 Infacare Pharmaceutical Corp Fremstilling i stor skala af stannsoporfin med høj renhed
PT2691398T (pt) 2011-03-30 2017-01-02 Infacare Pharmaceutical Corp Métodos para sintetizar mesoporfirinas de metal
CN104644557B (zh) * 2013-11-22 2017-10-31 上海宣泰医药科技有限公司 卟啉铁固体分散体及其制备方法
WO2017075518A1 (en) * 2015-10-29 2017-05-04 Loma Linda University Integrated phototherapy apparatus and methods
AU2017263628A1 (en) * 2016-05-12 2018-12-06 Infacare Pharmaceutical Corporation Methods for treating hyperbilirubinemia with stannsoporfin and phototherapy
JP6540664B2 (ja) * 2016-08-30 2019-07-10 株式会社三洋物産 遊技機
EP3462176A1 (en) * 2017-09-29 2019-04-03 Universität Basel Method and computer program for predicting bilirubin levels in neonates
WO2021126855A1 (en) * 2019-12-16 2021-06-24 Mallinckrodt Hospital Products IP Unlimited Company Methods for treating progressive hyperbilirubinemia
CN118506984B (zh) * 2024-07-17 2024-10-29 南京医科大学 一种早产儿母乳强化剂个体化管理系统

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003101999A2 (en) 2002-06-04 2003-12-11 Wellspring Pharmaceutical Corporation Preparation of metal mesoporphyrin halide compounds
US7375216B2 (en) 2002-06-04 2008-05-20 Infacare Pharmaceutical Corporation Preparation of metal mesoporphyrin compounds
DK2079472T3 (da) * 2006-10-04 2011-10-31 Infacare Pharmaceutical Corp Fremstilling i stor skala af stannsoporfin med høj renhed
BRPI0717774A2 (pt) * 2006-10-04 2014-04-29 Infacare Pharmaceutical Corp Tratamento de hiperbilirrubinemia em recém-nascidos que utiliza baixas dosagens de estansoporfina

Also Published As

Publication number Publication date
IL232791B (en) 2019-02-28
IL232791A0 (en) 2014-07-31
US20130158362A1 (en) 2013-06-20
AU2016203281A1 (en) 2016-06-09
AU2016203281B2 (en) 2017-07-13
EP3517115A3 (en) 2019-08-21
EP2788002A1 (en) 2014-10-15
AU2012345646A1 (en) 2014-06-26
JP2015500243A (ja) 2015-01-05
KR20140107355A (ko) 2014-09-04
AU2017236044A1 (en) 2017-10-26
IL260077A (en) 2018-07-31
JP2019052176A (ja) 2019-04-04
JP2018012717A (ja) 2018-01-25
EP3517115A2 (en) 2019-07-31
EP2788002A4 (en) 2015-06-03
CN104080457A (zh) 2014-10-01
US20200016167A1 (en) 2020-01-16
CN110279699A (zh) 2019-09-27
CA2857153A1 (en) 2013-06-06
WO2013082559A1 (en) 2013-06-06

Similar Documents

Publication Publication Date Title
IL260077A (en) Methods of treating excess bilirubin in the blood with stanoporfin
EP2760359A4 (en) METHOD FOR TREATING EYE STATES
HK1186748A1 (zh) 烴處理工藝
EP2753275A4 (en) METHODS OF TREATING OCULAR CONDITIONS
HUE048876T2 (hu) Rákos megbetegedések kezelése
PL2747565T3 (pl) Sposoby zaprawiania nasion
ZA201208219B (en) Method for treating wasterwater
IL228644A0 (en) Cancer treatment methods
HK1202297A1 (en) Methods for treating acne
GB201121950D0 (en) Treatment process
HK1209040A1 (en) Methods for treating vestibulotoxicity
ZA201308117B (en) Avian-based treatment
GB201105523D0 (en) Treatment method
GB201118482D0 (en) Treating tumours
GB201119181D0 (en) Light treatment method
GB201119184D0 (en) Light treatment method
GB201118869D0 (en) Light treatment method
GB201116328D0 (en) Treatment for tumours
GB201111247D0 (en) Treatment
GB201109119D0 (en) Treatment
GB201102288D0 (en) Treatment
GB201102269D0 (en) Treatment
GB201102265D0 (en) Treatment
GB201102263D0 (en) Treatment
GB201102266D0 (en) Treatment